- Home
- MCRB
as of 02-24-2026 4:00pm EST
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 139.7M | IPO Year: | 2015 |
| Target Price: | $14.33 | AVG Volume (30 days): | 93.5K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.40 | EPS Growth: | 100.00 |
| 52 Week Low/High: | $0.36 - $29.98 | Next Earning Date: | 01-01-0001 |
| Revenue: | $126,325,000 | Revenue Growth: | 1672.24% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | 3.43 | Index: | N/A |
| Free Cash Flow: | -148989000.0 | FCF Growth: | N/A |
AI-Powered MCRB Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
See Remarks
Avg Cost/Share
$8.47
Shares
75
Total Value
$635.25
Owned After
8,557
SEC Form 4
See Remarks
Avg Cost/Share
$8.47
Shares
78
Total Value
$660.66
Owned After
7,789
SEC Form 4
Director
Avg Cost/Share
$8.47
Shares
259
Total Value
$2,193.73
Owned After
11,577
SEC Form 4
See Remarks
Avg Cost/Share
$8.47
Shares
89
Total Value
$753.83
Owned After
7,677
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Feb 15, 2026 | Sell | $8.47 | 75 | $635.25 | 8,557 | |
| DesRosier Thomas | MCRB | See Remarks | Feb 15, 2026 | Sell | $8.47 | 78 | $660.66 | 7,789 | |
| Shaff Eric D. | MCRB | Director | Feb 15, 2026 | Sell | $8.47 | 259 | $2,193.73 | 11,577 | |
| Henn Matthew R. | MCRB | See Remarks | Feb 15, 2026 | Sell | $8.47 | 89 | $753.83 | 7,677 |
Compare MCRB vs Leading Stocks
See how MCRB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.